Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer

Background: CUR is a promising drug candidate based on its good bioactivity, but use of CUR is potentially restricted because of its poor solubility and bioavailability. Aim: The aim of this study was to prepare an aqueous formulation of curcumin nanosuspension (CUR-NS) to improve its solubility and change its in vivo behavior. Methods: CUR-NS was prepared by high-pressure homogenization method. Drug state in CUR-NS was evaluated by powder X-ray diffraction. Pharmacokinetics and biodistribution of CUR-NS after intravenous administration in rabbits and mice were studied. Results: The solubility and dissolution of CUR in the form of CUR-NS were significantly higher than those of crude CUR. X-ray crystallography diffraction indicated that the crystalline state of CUR in nanosuspension was preserved. Pharmacokinetics and biodistribution results of CUR-NS after intravenous administration in rabbits and mice showed that CUR-NS presented a markedly different pharmacokinetic property as compared to the CUR solution. AUC0−∞ of CUR-NS (700.43 ± 281.53 μg/mL, min) in plasma was approximately 3.8-fold greater than CUR solution (145.42 ± 9.29 μg/mL min), and the mean residence time (194.57 ± 32.18 versus 15.88 ± 3.56 minutes) was 11.2-fold longer. Conclusion: Nanosuspension could serve as a promising intravenous drug-delivery system for curcumin.

[1]  R. Lotan,et al.  Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. , 2009, Carcinogenesis.

[2]  Daniel Normolle,et al.  Dose escalation of a curcuminoid formulation , 2006, BMC complementary and alternative medicine.

[3]  K Borner,et al.  Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. , 2000, The Journal of antimicrobial chemotherapy.

[4]  Suchittra Samuhasaneeto,et al.  Curcumin Decreased Oxidative Stress, Inhibited NF-κB Activation, and Improved Liver Pathology in Ethanol-Induced Liver Injury in Rats , 2009, Journal of biomedicine & biotechnology.

[5]  R. Müller,et al.  Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. , 2000, International journal of pharmaceutics.

[6]  J. M. Lanao,et al.  Delivery systems to increase the selectivity of antibiotics in phagocytic cells. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Raviraj Pillai,et al.  Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. , 2008, Drug development and industrial pharmacy.

[8]  D. Karunagaran,et al.  Sensitization of Taxol-induced Apoptosis by Curcumin Involves Down-regulation of Nuclear Factor-κB and the Serine/Threonine Kinase Akt and Is Independent of Tubulin Polymerization* , 2005, Journal of Biological Chemistry.

[9]  X. Li,et al.  Preparation and Characterization of Solid Lipid Nanoparticles Containing Silibinin , 2007, Drug delivery.

[10]  V. Rangnekar,et al.  Spleen Tyrosine Kinase (Syk), a Novel Target of Curcumin, Is Required for B Lymphoma Growth1 , 2007, The Journal of Immunology.

[11]  Shishir,et al.  [ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY] The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease Volume 595 || REGULATION OF COX AND LOX BY CURCUMIN , 2007 .

[12]  Patrick Augustijns,et al.  Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.

[13]  M. Mayersohn,et al.  Sensitive and rapid isocratic liquid chromatography method for the quantitation of curcumin in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  A. Astier,et al.  Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Jochem Alsenz,et al.  The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. , 2003, Journal of pharmaceutical sciences.

[16]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[17]  G Vergnault,et al.  Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.

[18]  Thorsteinn Loftsson,et al.  Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. , 2002, International journal of pharmaceutics.

[19]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. , 2004, Current medicinal chemistry.

[20]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  Wenting Dai,et al.  Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. , 2008, International journal of pharmaceutics.

[22]  Lieven Baert,et al.  Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  B. Aggarwal,et al.  The molecular targets and therapeutic uses of curcumin in health and disease , 2007 .

[24]  Lisbeth Illum,et al.  Long circulating microparticulate drug carriers , 1995 .

[25]  Xueming Li,et al.  Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats , 2009, Drug development and industrial pharmacy.

[26]  J. Woodcock,et al.  The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.

[27]  G Vergnault,et al.  Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. , 2007, Advanced drug delivery reviews.

[28]  Rainer H Müller,et al.  Production and characterization of Hesperetin nanosuspensions for dermal delivery. , 2009, International journal of pharmaceutics.

[29]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  Peter W Voorhees,et al.  The theory of Ostwald ripening , 1985 .

[31]  G. Zhai,et al.  Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin. , 2008, Colloids and surfaces. B, Biointerfaces.

[32]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[33]  R. Müller,et al.  Kinetic solubility and dissolution velocity of rutin nanocrystals. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  S. Feng,et al.  In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. , 2006, Biomaterials.

[35]  A. Lundqvist,et al.  Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development , 2009, Drug development and industrial pharmacy.

[36]  Y. Hemar,et al.  A diffusing wave spectroscopy study of the kinetics of Ostwald ripening in protein-stabilised oil/water emulsions , 1999 .

[37]  T. Schiano,et al.  Efficacy of water-soluble vitamin E in the treatment of vitamin E malabsorption in short-bowel syndrome. , 1994, The American journal of clinical nutrition.

[38]  D. Brocks,et al.  High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. , 2007, Biomedical chromatography : BMC.

[39]  B. Aggarwal,et al.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. , 2009, The international journal of biochemistry & cell biology.

[40]  Q. Ping,et al.  Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. , 2008, International journal of pharmaceutics.

[41]  J. Silverman,et al.  Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). , 1999, Pharmaceutical research.

[42]  L. Mu,et al.  Application of TPGS in polymeric nanoparticulate drug delivery system. , 2006, Colloids and surfaces. B, Biointerfaces.

[43]  T. Tan,et al.  Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies , 2007, Drug development and industrial pharmacy.

[44]  Gérard Hopfgartner,et al.  P‐Glycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption , 2005, Clinical pharmacology and therapeutics.

[45]  J. Silverman,et al.  Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) , 1999, Pharmaceutical Research.

[46]  Sanjay Garg,et al.  Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. , 2009, International journal of pharmaceutics.

[47]  M. Radosz,et al.  Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy. , 2006, Colloids and surfaces. B, Biointerfaces.

[48]  Dianrui Zhang,et al.  Preparation and Characterization of an Oridonin Nanosuspension for Solubility and Dissolution Velocity Enhancement , 2007, Drug development and industrial pharmacy.